23 October 2018 | News
The revolutionary CPNsᵀᴹ are set to transform the market with their exceptional photostability, highly specific targeting and unique magnetic core
Stream Bio Ltd, a company that develops and manufactures a range of revolutionary bioimaging molecular probes, is expanding the distribution network of its transformative Conjugated Polymer Nanoparticle (CPNTM) products across Europe. New agreements with life science distributors CliniSciences and Biotrend will make its products available for purchase in France and Germany respectively.
Invented in the research labs of King’s College London, Stream Bio’s CPNsTMrepresent a new generation of novel molecular bioimaging probes. These highly fluorescent, non-toxic nanoparticles are set to revolutionise the bioimaging market with their unique brightness, exceptional stability, magnetic capability and suitability to be conjugated with a range of molecules.
The novel probes have already been launched in the UK and Ireland with 2BScientific. Distributing with CliniSciences and Biotrend, companies that market high quality products for in vitro research and diagnostics, is a major step forward for Stream Bio and its on-going plan to distribute worldwide.
Available for purchase as of today, Stream Bio’s CPNsTMcome in four emission wavelengths 475, 510, 550 and 680 nm, covering colours blue, green, yellow and red. Stream Bio’s CPNsTMcurrently have applications in diagnostics and therapeutics and have potential to be used in tumour imaging and fluorescence-guided surgery.
Stream Bio’s CEO, Andy Chaloner, said: “After the initial launch of our products in the UK and Ireland, we are delighted that our CPNsTM can now also be purchased in Europe. As a start-up biotech company, there is nothing better than seeing your product successfully brought to market. It’s an appreciation of all the hard work and a credit to the entire team at Stream Bio.”